First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

MLA

Arancha Bermúdez, et al. “First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial.” Blood, vol. 134, Nov. 2019, p. 143. EBSCOhost, https://doi.org/10.1182/blood-2019-122895.

APA

Arancha Bermúdez, Sandy W. Wong, William I. Bensinger, Maria-Victoria Mateos, Luciano J. Costa, Jesús F. San-Miguel, Rafael Sarmiento, Enrique M. Ocio, Paula Rodriguez-Otero, Allison Gaudy, Pilar Lardelli, Shaoyi Li, Javier de la Rubia, Kristen Hege, Lisa M. Kelly, Isaac Boss, & Michael R. Burgess. (2019). First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood, 134, 143. https://doi.org/10.1182/blood-2019-122895

Chicago

Arancha Bermúdez, Sandy W. Wong, William I. Bensinger, Maria-Victoria Mateos, Luciano J. Costa, Jesús F. San-Miguel, Rafael Sarmiento, et al. 2019. “First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial.” Blood 134 (November): 143. doi:10.1182/blood-2019-122895.